Organogenesis Reports Q3 2026 Revenue Decline Amid Reimbursement Policy Shifts
Organogenesis Holdings Inc. (ORGO) reported a sharp decline in third-quarter 2026 net product revenue, falling to $45.5 million—a 70% decrease year-over-year. The downturn was primarily driven by market contraction following the withdrawal of Local Coverage Determination policies and clinician confusion regarding discarded product rules for Advanced Wound Care products like Apligraf. Despite the revenue slump, the company implemented aggressive cost-control measures, reducing GAAP operating expenses by 42% through restructuring. While the company reported a GAAP net loss of $29.6 million compared to a profit in the prior year, management noted a 6% sequential revenue increase from Q2 2026 and an improvement in market share. However, regulatory hurdles at the Norwood facility have extended the PDUFA target date for Amnuvx.
Tickers: $ORGO
Topics: Guidance Market Contraction Net Loss Restructuring Revenue Decline